Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Net Cash Flow: 2013-2024

Historic Net Cash Flow for Aclaris Therapeutics (ACRS) over the last 12 years, with Dec 2024 value amounting to -$15.3 million.

  • Aclaris Therapeutics' Net Cash Flow fell 100.59% to -$146,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.4 million, marking a year-over-year decrease of 360.07%. This contributed to the annual value of -$15.3 million for FY2024, which is 183.53% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Net Cash Flow stood at -$15.3 million for FY2024, which was down 183.53% from -$5.4 million recorded in FY2023.
  • Over the past 5 years, Aclaris Therapeutics' Net Cash Flow peaked at $17.9 million during FY2022, and registered a low of -$15.3 million during FY2024.
  • Moreover, its 3-year median value for Net Cash Flow was -$5.4 million (2023), whereas its average is -$926,333.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 239.16% in 2022, then tumbled by 183.53% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Net Cash Flow (Yearly) stood at -$13.9 million in 2020, then skyrocketed by 138.10% to $5.3 million in 2021, then soared by 239.16% to $17.9 million in 2022, then crashed by 130.11% to -$5.4 million in 2023, then tumbled by 183.53% to -$15.3 million in 2024.